These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nevada
|
26-1407544
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
|
Large accelerated filer
|
o
|
Accelerated filer
o
|
|
Non-accelerated filer
|
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
þ
|
|
Page
|
||
|
|
||
|
Special Note Regarding Forward-Looking Statements
|
3
|
|
|
|
3
|
|
|
Item 1A. Risk Factors
|
10
|
|
|
Item 2. Properties
|
17
|
|
|
Item 3. Legal Proceedings
|
17
|
|
|
|
17
|
|
|
PART II
|
||
|
|
18
|
|
|
Item 6. Selected Financial Data
|
18
|
|
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
18
|
|
|
Item 8. Financial Statements and Supplementary Data
|
27
|
|
|
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
27
|
|
|
Item 9A. Controls and Procedures
|
27
|
|
|
Item 9B. Other Information
|
28
|
|
|
PART III
|
||
|
Item 10. Directors, Executive Officers and Corporate Governance
|
29
|
|
|
Item 11. Executive Compensation
|
34
|
|
|
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
37
|
|
|
Item 13. Certain Relationships and Related Transactions, and Director Independence
|
39
|
|
|
Item 14. Principal Accounting Fees and Services
|
40
|
|
|
|
||
|
Item 15. Exhibits and Financial Statement Schedules
|
40
|
|
|
Index to Financial Statements
|
45
|
|
|
Signatures
|
73
|
|
●
|
Leverage Approved Feedstock Pathways.
When economically advantageous, utilizing grain sorghum as lower carbon advanced biofuel feedstock for the production of ethanol. This also includes using our approved feedstock Pathway (in combination with biogas and CHP) for the production of Advanced Biofuels and associated higher value D5 Renewable Identification Numbers (RINs) and the subsequent qualification of the Keyes facility as an Advanced Biofuel producer.
|
|
●
|
Leverage the Keyes plant infrastructure and location.
Through its strategic location near the Port of Stockton and adjacent access to the Union Pacific railroad, Aemetis Keyes can, and has, procured grain sorghum from both international and domestic sources. Additionally, the Keyes facility has ready access to biogas through its existing infrastructure for the production of Advanced Biofuels under the approved EPA Pathway. Aemetis has also entered into a multi-year contract with Chromatin, Inc., an advanced grain sorghum seed and technology provider, to establish a multi-thousand acre local grain sorghum growing program with farmers in California’s Central Valley.
|
|
●
|
Leverage technology for the development and production of additional Advanced Biofuels and renewable specialty chemicals.
In July 2011, we acquired Zymetis, Inc., a biochemical research and development firm, with several patents pending and in-process R&D utilizing the Z-microbe™ to produce renewable chemicals and advanced fuels from renewable feedstocks. Our objective is to continue to commercialize this technology and expand the production of advanced biofuel technologies and other bio-chemicals in the United States.
|
|
●
|
Diversify revenue streams by continuing to develop value-add byproduct processing systems and processes
.
During April 2012, we installed corn oil extraction processes at the Keyes plant and began extracting corn oil for sale into the livestock feed market beginning in May 2012. We continue to evaluate and, as allowed by available financing and incremental profitability, adopt additional value-add processes that allow for a continued increase in the value-chain for corn oil as well as other byproducts.
|
|
●
|
Evaluate and pursue technology acquisition opportunities.
We intend to evaluate and pursue opportunities to acquire technologies and processes that result in accretive value opportunities as financial resources and business prospects make the acquisition of these technologies advisable. In addition, we may also seek to acquire companies or form licensing agreements or joint ventures with companies that offer prospects for the adoption of accretive technologies.
|
|
●
|
Capitalize on actions by the Government of India to reduce the subsidies on diesel.
We plan to develop marketing channels for the traditional bulk and transportation biodiesel markets, which are more economically viable as a result of the reduction of subsidies on petroleum diesel.
|
|
●
|
Expand alternative market demand for biodiesel and its byproducts.
We plan to create additional demand for our biodiesel and its byproducts by looking for alternative markets. In 2011, we began selling biodiesel to textile manufacturers. In the first quarter of 2012, we completed glycerin refining and oil pre-treatment units and began selling refined glycerin to manufacturers of paints and adhesives. In 2012, our India subsidiary received an Indian Pharmacopeia license, which enables it to sell refined glycerin to the pharmaceutical industry in India.
|
|
●
|
Continue to develop international markets.
We expect to increase sales by selling our biodiesel into the international market during the summer months, when biodiesel use in Europe increases with the onset of warmer weather. In 2012, we had no international sales, and, in 2013, we had sales of $11.6 million into the European market.
|
|
●
|
Diversify our feedstocks and products.
We designed our Kakinada plant with the capability to produce biodiesel from multiple feedstocks. In 2009, we began to produce biodiesel from NRPO (natural refined palm oil). In 2012, we completed an oil pre-treatment unit, which enables us to convert crude palm oil into refined palm oil, which can either be sold or used to produce biodiesel. In 2014 we completed the construction of a biodiesel distillation column, which will allow us to produce a high-quality biodiesel product meeting European Union standards.
|
|
2013
|
2012
|
% Change
|
||||||||||
|
Ethanol
|
||||||||||||
|
Gallons Sold (in 000s)
|
42,390 | 53,038 | (20 | )% | ||||||||
|
Average Sales Price/Gallon
|
$ | 2.62 | $ | 2.50 | 5 | % | ||||||
|
WDG
|
||||||||||||
|
Tons Sold (in 000s)
|
301 | 380 | (2 | )% | ||||||||
|
Average Sales Price/Ton
|
$ | 100.47 | $ | 103.23 | (3 | )% | ||||||
|
2013
|
2012
|
% Change
|
||||||||||
|
Biodiesel
|
||||||||||||
|
Tons sold
(1)
|
19,354 | 4,127 | 369 | % | ||||||||
|
Average Sales Price/Ton
|
$ | 929 | $ | 1,158 | (26 | )% | ||||||
|
Crude Glycerin
|
||||||||||||
|
Tons sold
|
- | 9 | (100 | )% | ||||||||
|
Average Sales Price/Ton
|
- | $ | 2,171 | (100 | )% | |||||||
|
Refined Glycerin
|
||||||||||||
|
Tons sold
|
4,913 | 2,280 | 115 | % | ||||||||
|
Average Sales Price/Ton
|
$ | 940 | $ | 981 | (4 | )% | ||||||
|
NRPO / Stearin
|
||||||||||||
|
Tons Sold
|
8,227 | 6,552 | (39 | )% | ||||||||
|
Average Sales Price/Ton
|
$ | 980 | $ | 994 | 140 | % | ||||||
|
CPO
|
||||||||||||
|
Tons Sold
|
2,000 | - | 100 | % | ||||||||
|
Average Sales Price/Ton
|
$ | 958 | - | 100 | % | |||||||
|
(1)
|
1 metric ton is equal to 1,000 kilograms (approximately 2,204 pounds).
|
|
|
●
|
incur additional debt;
|
|
|
●
|
make certain capital expenditures;
|
|
|
●
|
incur or permit liens to exist;
|
|
|
●
|
enter into transactions with affiliates;
|
|
|
●
|
guarantee the debt of other entities, including joint ventures;
|
|
|
●
|
merge or consolidate or otherwise combine with another company; and
|
|
|
●
|
transfer, sell or lease our assets
|
|
Quarter Ending
|
High Bid
|
Low Bid
|
||||||
|
March 31, 2012
|
$ | 1.00 | $ | 0.53 | ||||
|
June 30, 2012
|
$ | 0.85 | $ | 0.37 | ||||
|
September 30, 2012
|
$ | 0.82 | $ | 0.37 | ||||
|
December 31, 2012
|
$ | 0.73 | $ | 0.35 | ||||
|
March 31, 2013
|
$ | 0.83 | $ | 0.43 | ||||
|
June 30, 2013
|
$ | 0.59 | $ | 0.25 | ||||
|
September 30, 2013
|
$ | 0.45 | $ | 0.30 | ||||
|
December 31, 2013
|
$ | 0.32 | $ | 0.15 | ||||
|
|
●
|
Overview. Discussion of our business and overall analysis of financial and other highlights affecting us, to provide context for the remainder of MD&A.
|
|
|
●
|
Results of Operations. An analysis of our financial results comparing the twelve months ended December 31, 2013 to the twelve months ended December 31, 2012.
|
|
|
●
|
Liquidity and Capital Resources. An analysis of changes in our balance sheets and cash flows and discussion of our financial condition.
|
|
|
●
|
Critical Accounting Estimates. Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
|
|
Fiscal Year Ended December 31 (in thousands)
|
||||||||||||||||
|
2013
|
2012
|
Increase/(Decrease)
|
Percentage Change
|
|||||||||||||
|
North America
|
$ | 144,698 | $ | 175,501 | $ | (30,803 | ) | (17.6 | )% | |||||||
|
India
|
32,816 | 13,548 | 19,268 | 142.2 | % | |||||||||||
|
Total
|
$ | 177,514 | $ | 189,049 | $ | (11,535 | ) | (6.1 | )% | |||||||
|
Fiscal Year Ended December 31 (in thousands)
|
||||||||||||||||
|
2013
|
2012
|
Increase/(Decrease)
|
Percentage Change
|
|||||||||||||
|
North America
|
$ | 130,498 | $ | 183,784 | $ | (53,286 | ) | (29.0 | )% | |||||||
|
India
|
28,722 | 14,191 | 14,531 | 102.4 | % | |||||||||||
|
Total
|
$ | 159,220 | $ | 197,975 | $ | (38,755 | ) | (19.6 | )% | |||||||
|
Fiscal Year Ended December 31 (in thousands)
|
||||||||||||||||
|
2013
|
2012
|
Increase/(Decrease)
|
Percentage Change
|
|||||||||||||
|
North America
|
$ | 539 | $ | 620 | $ | (81 | ) | (13.1 | )% | |||||||
|
India
|
- | - | - | - | ||||||||||||
|
Total
|
$ | 539 | $ | 620 | $ | (81 | ) | (13.1 | )% | |||||||
|
Fiscal Year Ended December 31 (in thousands)
|
||||||||||||||||
|
2013
|
2012
|
Increase/(Decrease)
|
Percentage Change
|
|||||||||||||
|
North America
|
$ | 12,428 | $ | 10,922 | $ | 1,506 | 13.8 | % | ||||||||
|
India
|
2,847 | 691 | 2,156 | 312.0 | % | |||||||||||
|
Total
|
$ | 15,275 | $ | 11,613 | $ | 3,662 | 31.5 | % | ||||||||
|
|
●
|
Interest expense is attributable to debt facilities of the Company, our subsidiaries Universal Biofuels Pvt. Ltd., International Biofuels, Inc., AE Advanced Fuels Keyes, Inc. and interest accrued on the complaint filed by Cordillera Fund, L.P. These debt facilities included revenue participation fees, warrants issued as fees and the payment of other fees and discount fees, which are amortized under amortization expense. The fair value of stock and warrants are amortized through amortization expense, except when the extinguishment accounting method is applied, where refinanced debt costs are recorded through the extinguishment expense account. We incurred interest, amortization and loss on debt extinguishment expense of approximately $28.0 million for the twelve months ended December 31, 2013 ($0.8 million from India loans and $27.2 million from North America loans) compared to $26.7 million for the twelve months ended December 31, 2012 ($4.4 million from India loans and $22.3 million from North America loans) principally due to the additional debt associated with the acquisition of the Keyes, CA plant.
|
|
|
●
|
On July 6, 2012 we acquired Cilion, Inc. through a merger. The excess of the fair value of the assets acquired gave rise to a gain on bargain purchase accounting of $42.3 million for the year ended December 31, 2012.
|
|
|
●
|
Some of the equipment acquired during the Cilion merger sold for a gain of $0.1 million and some of the equipment was classified as held for sale during 2012. The equipment held for sale was sold for a gain of $0.2 million during 2013.
|
|
|
●
|
During 2012 we sold our land holding in Sutton, Nebraska at a gain of $236,830.
|
|
●
|
During 2013, we settled several past outstanding liabilities and accordingly recognized a gain of $0.6 million in other income.
|
|
|
December 31,
2013
|
December 31,
2012
|
||||||
|
Cash and cash equivalents
|
$ | 4,925,820 | $ | 290,603 | ||||
|
Current assets (including cash, cash equivalents, and deposits)
|
12,706,908 | 6,845,449 | ||||||
|
Current liabilities (including short term debt)
|
36,116,546 | 57,835,203 | ||||||
|
Short and long term debt
|
91,758,183 | 70,045,595 | ||||||
|
(1)
|
Ineffective controls exist to ensure that the accounting and reporting for complex accounting transactions are recorded in accordance with GAAP.
|
|
●
|
A number of significant audit adjustments were made to the general ledger, which collectively could have a material effect on the financial statements. These adjustments were made up of entries to properly record the carrying value of debt issue costs, warrant accounting and various other adjustments summarized in our Report to the Audit Committee communication.
|
|
●
|
As part of our review of the financial statements included in the 10-K, we also made significant revisions to the statement of cash flows and various notes to the financial statements, which indicate that additional controls over disclosures need to be evaluated.
|
|
(1)
|
Increase our efforts to educate both our existing and expanded accounting policy and control organization on the application of the internal control structure;
|
|
(2)
|
Emphasize with management the importance of our internal control structure;
|
|
(3)
|
Seek outside consulting services where our existing accounting policy and control organization believes the complexity of the existing exceeds our internal capabilities.
|
|
Name
|
Age
|
Position
|
Director
Since
|
|||
|
Eric A. McAfee
|
51
|
Chief Executive Officer and Chairman of the Board
|
2006
|
|||
|
Francis P. Barton
|
67
|
Director
|
2012
|
|||
|
John R. Block
|
79
|
Director
|
2008
|
|||
|
Dr. Steven W. Hutcheson
|
60
|
Director
|
2011
|
|||
|
Harold Sorgenti
|
79
|
Director
|
2007
|
|
Name
|
Age
|
Position
|
||
|
Eric A. McAffe
|
51
|
Chief Executive Officer and Chairman of the Board
|
||
|
Andrew B. Foster
|
48
|
Executive Vice President and Chief Operating Officer
|
||
|
Sanjeev Gupta
|
54
|
Executive Vice President and Managing Director, Chairman and President of Universal Biofuels Private, Ltd.
|
||
|
Todd Waltz
|
52
|
Executive Vice President, Chief Financial Officer and Secretary
|
|
Name of Director
|
Audit
|
Governance, Compensation and
Nominating
|
||
|
Harold Sorgenti
|
M
|
C
|
||
|
Francis Barton*
|
C
|
M
|
||
|
John R. Block*
|
M
|
|||
|
Dr. Hutcheson*
|
M
|
|||
|
M = Member
|
||||
|
C = Chair
|
|
|
*
|
Mr. Barton was appointed to the Company’s Board and Audit Committees on August 2, 2012.
|
|
|
*
|
Mr. Block was appointed to the Audit Committee on July 14, 2011.
|
|
|
*
|
Dr. Hutcheson was appointed to the Governance, Compensation and Nominating Committee on July 14, 2011.
|
|
Name and Principal Position
|
Year
|
Salary ($)
|
Bonus ($)
|
Option/ Warrant Awards
(1)
($)
|
Total Compensation ($)
|
||
|
Eric A. McAfee, Chief
(2)
Executive Officer
|
2013
|
180,000
|
-
|
180,000
|
|||
|
2012
|
180,000
|
-
|
180,000
|
||||
|
Andrew B. Foster, Executive Vice President
|
2013
|
180,000
|
9,000
|
76,262
|
265,262
|
||
|
2012
|
180,000
|
84,047
|
264,047
|
||||
|
Sanjeev Gupta, Executive Vice President
|
2013
|
180,000
|
9,000
|
184,394
|
373,394
|
||
|
2012
|
180,000
|
84,047
|
264,047
|
||||
|
Todd A. Waltz, Chief Financial Officer
|
2013
|
180,000
|
9,000
|
184,394
|
373,394
|
||
|
2012
|
180,000
|
84,047
|
264,047
|
||||
|
(1)
|
These amounts reflect the value determined by the Company for accounting purposes for these awards with respect to the current fiscal year and do not reflect whether the recipient has actually realized a financial benefit from the awards (such as by exercising stock options). This column represents the aggregate grant date fair value of stock options and warrants granted during fiscal year 2013 and 2012 to each of the named executive officers, in accordance with ASC Topic 718
Compensation
. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. The assumptions made when calculating the amounts in this table are found in Note 11 (Stock Based Compensation) of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K
|
|
(2)
|
Mr. McAfee’s compensation is solely for his services as an Executive Officer and he does not receive any compensation for his services as Chairman of the Board of Directors
|
|
Option/Warrant Awards
|
|||||||||||||
|
Name
|
|
Award
Date
|
|
No. of
Securities
underlying unexercised
options (#) exercisable
|
|
No. of
securities underlying unexercised
options (#) unexercisable
|
|
Equity incentive
plan awards:
# of securities underlying unexercised
unearned
options (#)
|
|
Option exercise
price ($)
|
|
Option expiration date
|
|
|
Andrew B. Foster
|
08/02/13
|
150,000
(4)
|
0.40
|
8/3/18
|
|||||||||
|
03/14/13
|
16,667
(2)
|
83,333
|
0.65
|
3/13/18
|
|||||||||
|
11/05/12
|
100,000
(2)
|
200,000
|
0.55
|
11/05/17
|
|||||||||
|
12/09/10
|
8,837
(1)
|
0.12
|
12/08/15
|
||||||||||
|
12/09/10
|
41,163
(1)
|
0.13
|
12/15/15
|
||||||||||
|
3/17/10
|
50,000
(1)
|
0.21
|
3/17/15
|
||||||||||
|
5/21/09
|
480,000
(1)
|
0.16
|
5/20/14
|
||||||||||
|
7/17/07
|
300,000
(1)
|
3.00
|
7/16/17
|
||||||||||
|
Sanjeev Gupta
|
08/02/13
|
300,000
(4)
|
0.40
|
8/3/18
|
|||||||||
|
03/14/13
|
50,000
(2)
|
250,000
|
0.65
|
3/13/18
|
|||||||||
|
11/05/12
|
100,000
(2)
|
200,000
|
0.55
|
11/05/17
|
|||||||||
|
12/09/10
|
32,404
(2)
|
2,946
|
0.12
|
12/08/15
|
|||||||||
|
12/09/10
|
164,650
(1)
|
0.13
|
12/15/15
|
||||||||||
|
3/17/10
|
100,000
(1)
|
0.21
|
3/17/15
|
||||||||||
|
5/21/09
|
500,000
(1)
|
0.16
|
5/20/14
|
||||||||||
|
Todd A. Waltz
|
08/02/13
|
300,000
(4)
|
0.40
|
8/3/18
|
|||||||||
|
03/14/13
|
50,000
(2)
|
250,000
|
0.65
|
3/13/18
|
|||||||||
|
11/05/12
|
100,000
(2)
|
200,000
|
0.55
|
11/05/17
|
|||||||||
|
12/09/10
|
39,769
(2)
|
13,255
|
0.12
|
12/08/15
|
|||||||||
|
12/09/10
|
246,976
(1)
|
0.13
|
12/15/15
|
||||||||||
|
3/17/10
|
600,000
(1)
|
0.21
|
3/17/15
|
||||||||||
|
5/21/09
|
220,000
(1)
|
0.16
|
5/20/14
|
||||||||||
|
(1)
|
These shares were vested fully according to the grant and agreement terms and were exercisable according to terms of the agreement.
|
|
(2)
|
One-twelfth (1/12) of the shares subject to the option vest every three months from the date of grant.
|
|
(3)
|
Fifty percent (50%) of the shares subject to the option were exercisable on the date of grant and one-twenty-fourth (1/24) of the shares subject to the option vest every three months from the date of grant.
|
|
(4)
|
Warrants issued and fully vested on the date of grant.
|
|
Name
|
Fees Earned
or Paid in
Cash ($)
|
Option
Awards
(1)(2)
($)
|
Total ($)
|
|||||||||
|
2013
|
||||||||||||
|
Harold Sorgenti
|
90,250 | 105,857 | 196,107 | |||||||||
|
John R. Block
|
79,500 | 91,060 | 170,560 | |||||||||
|
Dr. Steven Hutcheson
|
78,750 | 91,060 | 169,810 | |||||||||
|
Francis Barton
|
106,333 | 105,857 | 212,190 | |||||||||
|
2012
|
||||||||||||
|
Michael Peterson
|
72,250 | – | 72,250 | |||||||||
|
Harold Sorgenti
|
103,750 | 46,813 | 150,563 | |||||||||
|
John R. Block
|
78,000 | 46,813 | 124,813 | |||||||||
|
Dr. Steven Hutcheson
|
79,250 | 38,036 | 117,286 | |||||||||
|
Francis Barton
|
46,250 | 84,047 | 130,297 | |||||||||
|
(1)
|
The amounts in this column represent the aggregate grant date fair value under ASC Topic 718. The assumptions made when calculating the amounts in this table are found in Note 11 (Stock Based Compensation) of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K .
|
|
(2)
|
The following table shows for each named individual the aggregate number of shares subject to all outstanding options and warrants held by that individual as of December 31, 2013.
|
|
Name
|
Number of Shares of Common Stock Subject to all outstanding options as of December 31, 2013
|
Number of Shares of Common Stock Subject to all outstanding warrants as of December 31, 2013
|
||
|
Harold Sorgenti
|
617,676
|
|
332,324
|
|
|
John R. Block
|
617,676
|
|
282,324
|
|
|
Dr. Steven Hutcheson
|
262,500
|
|
200,000
|
|
|
Francis Barton
|
400,000
|
|
250,000
|
|
Common Stock
|
Series B Preferred Stock
|
||||||||
|
Name and Address
|
|
Amount and
Nature of Beneficial
Ownership
|
Percentage
of Class
|
|
|
Amount and
Nature of
Beneficial Ownership
|
Percentage
of Class
|
||
|
Officers & Directors
|
|||||||||
|
Eric A. McAfee
(1)
|
34,916,159
|
17.45
|
%
|
||||||
|
Francis Barton
(2)
|
633,333
|
*
|
|||||||
|
John R. Block
(3)
|
783,333
|
*
|
|||||||
|
Dr. Steven Hutcheson
(4)
|
2,303,403
|
1.15
|
%
|
||||||
|
Harold Sorgenti
(5)
|
833,333
|
*
|
|||||||
|
Andrew Foster
(6)
|
1,155,000
|
*
|
|||||||
|
Sanjeev Gupta
(7)
|
1,525,000
|
*
|
|||||||
|
Todd A. Waltz
(8)
|
2,665,000
|
1.32
|
%
|
||||||
|
All officers and directors as a group (8 Persons)
|
44,614,561
|
21.69
|
%
|
||||||
|
5% or more Holders
|
|||||||||
|
Third Eye Capital
(9)
|
34,981,566
|
17.4
|
5%
|
||||||
|
161 Bay Street, Suite 3930
|
|||||||||
|
Toronto, Ontario M5J 2S1
|
|||||||||
|
Laird Cagan
(10)
|
24,648,872
|
12.32
|
%
|
||||||
|
20400 Stevens Creek Blvd., Suite 700
|
|||||||||
|
Cupertino, CA 95014
|
|||||||||
|
Michael Orsak
|
2,178,333
|
166,667
|
6.94
|
%
|
|||||
|
1125 San Mateo Drive,
|
|||||||||
|
Menlo Park, California 94025
|
|||||||||
|
David J. Lies
|
1,606,587
|
200,000
|
8.33
|
%
|
|||||
|
1210 Sheridan Road
|
|||||||||
|
Wilmette,Illinois 60091
|
|||||||||
|
Mahesh Pawani
|
535,358
|
400,000
|
16.66
|
%
|
|||||
|
Villa No. 6, Street 29, Community 317, Al Mankhool,
|
|||||||||
|
Dubai, United Arab Emirates
|
|||||||||
|
Frederick WB Vogel
|
440,678
|
408,332
|
17.01
|
%
|
|||||
|
1660 N. La Salle Drive, Apt 2411
|
|||||||||
|
Chicago,Illinois 60614
|
|||||||||
|
Fred Mancheski
|
-
|
300,000
|
12.49
|
%
|
|||||
|
1060 Vegas Valley Dr
|
|||||||||
|
Las Vegas, NV 89109
|
|||||||||
|
Crestview Capital, LLC
|
-
|
166,667
|
6.94
|
%
|
|||||
|
95 Revere Dr., Ste A
|
|||||||||
|
Northbrook,Illinois 60062
|
|||||||||
|
(1) Includes 34,116,159 shares held by McAfee Capital, LLC, a company owned by Mr. McAfee. McAfee Capital has directly or indirectly pledged all of these shares as security for Third Eye Capital debt arrangements.
|
|
(2) Includes 150,000 shares held by Mr. Barton and 233,333 shares pursuant to options exercisable within 60 days of February 28, 2014 and 250,000 common stock warrants fully exercisable.
|
|
(3) Includes 501,009 shares issuable pursuant to options exercisable within 60 days of February 28, 2014, and 282,324 common stock warrants fully exercisable.
|
|
(4) Includes 1,957,570 shares held by Mr. Hutcheson and 145,833 shares issuable pursuant to options exercisable within 60 days of February 28, 2014 and 200,000 common stock warrants fully exercisable.
|
|
(5) Includes 501,009 shares issuable pursuant to options exercisable within 60 days of February 28, 2014, and 332,324 common stock warrants fully exercisable.
|
|
(6) Includes 963,837 shares issuable pursuant to options exercisable within 60 days of February 28], 2014, and 191,163 fully exercisable common stock warrants.
|
|
(7) Includes 200,000 shares held by Mr. Gupta, 860,350 shares issuable pursuant to options exercisable within 60 days of February 28, 2014, and 464,650 fully exercisable common stock warrants.
|
|
(8) Includes 1,000,000 shares held by Mr. Waltz, 1,118,024 shares issuable pursuant to options exercisable within 60 days of February 28, 2014
and
546,976 fully exercisable common stock warrants.
|
|
(9) Includes 24,313,695 shares held by RBC Dexia Investor Services Trust, held in Trust for Account 110-455-262 and Sprott Private Credit Fund, LP, a corporation residing in Canada. Third Eye Capital funds beneficially own 10,284,538 common shares, and 383,333 common stock warrants fully exercisable.
|
|
(10) Includes (i) 21,290,626 shares held by Cagan Capital, LLC, a company owned by Mr. Cagan; (ii) 400,000 shares owned by the KRC Trust and 400,000 owned by the KQC Trust, trusts for Mr. Cagan’s daughters for which Mr. Cagan is trustee, (iii) 1,710,510 held by The Laird Cagan 2011 Grantor Retained Annuity Trust and (iv) 847,736 shares held by Mr. Cagan individually.
|
|
Plan category
|
Number of
securities
to be issued
upon exercise
of
outstanding
options/warrants
(a)
|
Weighted
average
exercise price
of
outstanding
options/warrants
(b)
|
Number of
securities
remaining
available
for future
issuance
under equity
compensation
plans (excluding
securities
reflected in
column (a))
(c) (2)
|
|||||||||
|
Equity compensation plans approved by security holders
(1)
|
9,127,497
|
$
|
0.49
|
744,466
|
||||||||
|
Equity in the form of warrants issued to officers, directors and employees not approved by security holders
|
3,092,623
|
$
|
0.23
|
—
|
||||||||
|
Equity in the form of options issued to directors and consultants not approved by security holders
|
977,500
|
$
|
0.55
|
—
|
||||||||
|
(1)
|
Shares from the 2006 Stock Plan and the 2007 Stock Plan.
|
|
(2)
|
Amount consists of shares available for future issuance under the 2006 Plan and 2007 Plan.
|
|
|
2013
|
2012
|
||||||
|
Audit Fees
|
$ |
260,000
|
$ |
325,000
|
||||
|
Audit-Related Fees
|
42,500
|
111,500
|
||||||
|
Total Audit and Audit-Related Fees
|
302,500 | 436,500 | ||||||
|
All Other Fees
|
––
|
2,305
|
||||||
|
Total
|
302,500
|
438,805 | ||||||
|
|
|
|
|
1. Financial Statements:
|
|
●
|
Report of Independent Registered Public Accounting Firm
|
|
●
|
Consolidated Balance Sheets
|
|
●
|
Consolidated Statements of Operations and Comprehensive Loss
|
|
●
|
Consolidated Statements of Cash Flows
|
|
●
|
Consolidated Statements of Stockholders’ Equity
|
|
●
|
Notes to Consolidated Financial Statements
|
|
INDEX TO EXHIBITS
|
||||||
|
Incorporated by Reference
|
|
|||||
|
Exhibit No.
|
Description
|
Form
|
File No.
|
Exhibit
|
Filing Date
|
Filed Herewith |
|
3.1.1
|
Articles of Incorporation
|
10-Q
|
000-51354
|
3.1
|
Nov. 14, 2008
|
|
|
3.1.2
|
Certificate of Amendment to Articles of Incorporation
|
10-Q
|
000-51354
|
3.1.1
|
Nov. 14, 2008
|
|
|
3.1.3
|
Certificate of Designation of Series B Preferred Stock
|
8-K
|
000-51354
|
3.2
|
Dec. 13, 2007
|
|
|
3.1.4
|
Certificate of Amendment to Articles of Incorporation
|
8-K
|
000-51354
|
3.3
|
Dec. 13, 2007
|
|
|
3.1.5
|
Certificate of Amendment to Articles of Incorporation
|
Pre14C
|
111136140
|
October 26, 2011
|
||
|
3.2.1
|
Bylaws
|
8-K
|
000-51354
|
3.4
|
Dec. 13, 2007
|
|
|
4.1
|
Specimen Common Stock Certificate
|
8-K
|
000-51354
|
4.1
|
Dec. 13, 2007
|
|
|
4.2
|
Specimen Series B Preferred Stock Certificate
|
8-K
|
000-51354
|
4.2
|
Dec. 13, 2007
|
|
|
4.3
|
Form of Common Stock Warrant
|
8-K
|
000-51354
|
4.3
|
Dec. 13, 2007
|
|
|
4.4
|
Form of Series B Preferred Stock Warrant
|
8-K
|
000-51354
|
4.4
|
Dec. 13, 2007
|
|
|
Amended and Restated 2007 Stock Plan
|
14A
|
000-51354
|
Apr. 15, 2008
|
X | ||
|
Amended and Restated 2007 Stock Plan form of Stock Option Award Agreement
|
14A
|
000-51354
|
Apr. 15, 2008
|
X | ||
|
10.3
|
Eric McAfee Executive Employment Agreement dated September 1, 2011
|
8-K
|
000-51354
|
10.2
|
Sep. 8, 2011
|
|
|
10.4
|
Andrew Foster Executive Employment Agreement, dated May 22, 2007
|
8-K
|
000-51354
|
10.7
|
Dec. 13, 2007
|
|
|
10.5
|
Todd Waltz Executive Employment Agreement, dated March 15, 2010
|
8-K
|
000-51354
|
May 20, 2009
|
||
|
10.6
|
Sanjeev Gupta Executive Employment Agreement, dated September 1, 2007
|
10-K
|
000-51354
|
10.11
|
May 20, 2009
|
|
|
10.7
|
Agreement of Loan for Overall Limit dated June 26, 2008 between Universal Biofuels Pvt Limited and State Bank of India
|
10-Q
|
000-51354
|
10.12
|
Aug. 14, 2008
|
|
|
10.8
|
Ethanol Marketing Agreement, dated October 29, 2010 between AE Advanced Fuels Keyes, Inc. and Kinergy Marketing, LLC
|
10-Q
|
000-51354
|
10.6
|
Dec. 1, 2010
|
|
|
Zymetis, Inc. 2006 Stock Incentive Plan
|
10-K
|
000-51354
|
10.31
|
October 31, 2012
|
X | |
|
Zymetis Inc. Incentive Stock Option Agreement
|
10-K
|
000-51354
|
10.32
|
October 31, 2012
|
X | |
|
Zymetis Inc. Non-Incentive Stock Option Agreement
|
10-K
|
000-51354
|
10.33
|
October 31, 2012
|
X | |
|
10.12
|
First Amendment to Ethanol Marketing Agreement dated September 6, 2011, between AE Advanced Fuels Keyes, Inc. and Kinergy Energy Marketing
|
8-K
|
000-51354
|
10.1
|
September 8, 2011
|
|
|
10.13
|
Form of Note and Warrant Purchase Agreement
|
8-K
|
000-51354
|
10.1
|
January 1, 2012
|
|
|
10.14
|
Form of 5% Subordinated Note
|
8-K
|
000-51354
|
10.2
|
January 1, 2012
|
|
|
10.15
|
Form of Common Stock Warrant
|
8-K
|
000-51354
|
10.3
|
January 1, 2012
|
|
|
10.16
|
Amendment No. 6 to Note Purchase Agreement dated April 13, 2012 among Aemetis Advanced Fuels Keyes, Inc., Third Eye Capital Corporation, as agent, and the Purchasers
|
8-K
|
000-51354
|
10.1
|
April 19, 2012
|
|
|
INDEX TO EXHIBITS
|
||||||
|
Incorporated by Reference
|
|
|||||
|
Exhibit No.
|
Description
|
Form
|
Film No.
|
Exhibit
|
Filing Date
|
Filed Herewith |
|
10.17
|
Limited Waiver to Note Purchase Agreement dated March 31, 2012 among Aemetis Advanced Fuels Keyes, Inc., and Third Eye Capital Corporation, an Ontario corporation, as agent
|
8-K
|
000-51354
|
10.1
|
April 19, 2012
|
|
|
10.18
|
Limited Waiver to Note and Warrant Purchase Agreement dated March 31, 2012 among Aemetis, Inc., Third Eye Capital Corporation, an Ontario corporation, as agent, and the Purchasers
|
8-K
|
000-51354
|
10.1
|
April 19, 2012
|
|
|
10.19
|
Amendment No. 7 to Note Purchase Agreement dated May 15, 2012 among Aemetis Advanced Fuels Keyes, Inc., Third Eye Capital Corporation, as agent, and the Purchasers
|
8-K
|
000-51354
|
10.1
|
May 22, 2012
|
|
|
10.20
|
Form of Note and Warrant Purchase Agreement
|
8-K
|
000-51354
|
10.1
|
June 6, 2012
|
|
|
10.21
|
Form of 5% Subordinated Note
|
8-K
|
000-51354
|
10.1
|
June 6, 2012
|
|
|
10.22
|
Form of Common Stock Warrant
|
8-K
|
000-51354
|
10.1
|
June 6, 2012
|
|
|
10.23
|
Note and Warrant Purchase Agreement dated June 21, 2012 among Third Eye Capital Corporation, Aemetis Advanced Fuels Keyes, Inc., and Aemetis, Inc.
|
8-K
|
000-51354
|
10.1
|
June 28, 2012
|
|
|
10.24
|
5% Subordinated Promissory Note dated June 21, 2012 among Third Eye Capital Corporation, Aemetis Advanced Fuels Keyes, Inc., and Aemetis, Inc.
|
8-K
|
000-51354
|
10.2
|
June 28, 2012
|
|
|
10.25
|
Form of Warrant to Purchase Common Stock
|
8-K
|
000-51354
|
10.3
|
June 28, 2012
|
|
|
10.26
|
Note Purchase Agreement dated June 27, 2012 among Third Eye Capital Corporation, Aemetis Advanced Fuels Keyes, Inc., and Aemetis, Inc.
|
8-K
|
000-51354
|
10.1
|
July 3, 2012
|
|
|
10.27
|
15% Subordinated Promissory Note dated June 27, 2012 among Third Eye Capital Corporation, Aemetis Advanced Fuels Keyes, Inc., and Aemetis, Inc.
|
8-K
|
000-51354
|
10.2
|
July 3, 2012
|
|
|
10.28
|
Agreement and Plan of Merger, dated July 6, 2012, among Aemetis, Inc., AE Advanced Fuels, Inc., Keyes Facility Acquisition Corp., and Cilion, Inc.
|
8-K
|
000-51354
|
2.1
|
July 10, 2012
|
|
|
10.29
|
Stockholders’ Agreement dated July 6, 2012, among Aemetis, Inc., and Western Milling Investors, LLC, as Security holders’ Representative.
|
8-K
|
000-51354
|
10.1
|
July 10, 2012
|
|
|
10.30
|
Amended and Restated Note Purchase Agreement, dated July 6, 2012 among Aemetis Advanced Fuels Keyes, Inc., Keyes Facility Acquisition Corp., Aemetis, Inc., Third Eye Capital Corporation, as Administrative Agent, and the Note holders
|
8-K
|
000-51354
|
10.2
|
July 10, 2012
|
|
|
10.31
|
Amended and Restated Guaranty, dated July 6, 2012 among Aemetis, Inc., certain subsidiaries of Aemetis and Third Eye Capital Corporation, as Agent.
|
8-K
|
000-51354
|
10.3
|
July 10, 2012
|
|
|
10.32
|
Amended and Restated Security Agreement, dated July 6, 2012 among Aemetis, Inc., certain subsidiaries of Aemetis and Third Eye Capital Corporation, as Agent.
|
8-K
|
000-51354
|
10.4
|
July 10, 2012
|
|
|
10.33
|
Investors’ Rights Agreement dated July 6, 2012, by and among Aemetis, Inc., and the investors listed on Schedule A thereto.
|
8-K
|
000-51354
|
10.5
|
July 10, 2012
|
|
|
10.34
|
Technology License Agreement dated August 9, 2012 between Chevron Lummus Global LLC and Aemetis Advanced Fuels, Inc.
|
8-K
|
000-51354
|
10.1
|
August 22, 2012
|
|
|
10.35
|
Corn Procurement and Working Capital Agreement dated March 9, 2011 between J.D. Heiskell Holdings LLC and Aemetis Advanced Fuels Keyes, Inc.*
|
10-K
|
000-51354
|
10.64
|
October 31, 2012
|
|
|
10.36
|
Purchasing Agreement dated March 9, 2011 between J.D. Heiskell Holdings LLC and Aemetis Advanced Fuels Keyes, Inc.*
|
10-K
|
000-51354
|
10.65
|
October 31, 2012
|
|
|
10.37
|
WDG Purchase and Sale Agreement dated March 23, 2011 between A.L. Gilbert Company and Aemetis Advanced Fuels Keyes, Inc.
|
10-K
|
000-51354
|
10.66
|
October 31, 2012
|
|
|
10.38
|
Keyes Corn Handling Agreement dated March 23, 2011 among A. L. Gilbert Company, AE Advanced Fuels Keyes, Inc., and J.D. Heiskell Holdings, LLC*
|
10-K
|
000-51354
|
10.67
|
October 31, 2012
|
|
|
10.39
|
Limited Waiver and Amendment No. 1 to Amended and Restated Note Purchase Agreement dated as of October 18, 2012 by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.
|
8-K
|
000-51354
|
10.1
|
October 23, 2012
|
|
|
10.40
|
Amendment No. 1 to Revolving Line of Credit Agreement dated October 16, 2012 by and among Aemetis International, Inc., a Nevada corporation, and Laird Q. Cagan
|
8-K
|
000-51354
|
10.2
|
October 23, 2012
|
|
INDEX TO EXHIBITS
|
||||||
|
Incorporated by Reference
|
|
|||||
|
Exhibit No.
|
Description
|
Form
|
Film No.
|
Exhibit
|
Filing Date
|
Filed Herewith |
|
10.41
|
Note Purchase Agreement effective as of March 4, 2011, amended January 19, 2012 and July 24, 2012 by and among AE Advanced Fuels, Inc., a Delaware corporation, and Advanced BioEnergy, LP a California limited partnership and Advanced BioEnergy GP, LLC, a California limited liability company.
|
8-K
|
000-51354
|
10.3
|
October 23, 2012
|
|
|
10.42
|
Form of Convertible Subordinated Promissory Note by and among AE Advanced Fuels, Inc., a Delaware corporation and Advanced BioEnergy, LP, a California limited partnership.
|
8-K
|
000-51354
|
10.4
|
October 23, 2012
|
|
|
10.43
|
Amendment to the Purchasing Agreement dated March 9, 2011 between J.D. Heiskell Holdings LLC and Aemetis Advanced Fuels Keyes, Inc. dated September 29, 2012
|
10-K
|
000-51354
|
10.72
|
April 4, 2013
|
|
|
10.44
|
Agreement for Repayment of Note by Share Issuance dated as of December 31, 2012 by and among Aemetis, Inc., Aemetis International, Inc., (formerly known as “International Biodiesel, Inc.”), a Nevada corporation and wholly-owned subsidiary of the Company, and Laird Q. Cagan for himself and on behalf of all other holders of interests in the Revolving Line of Credit (as defined in the Agreement).
|
8-K
|
000-51354
|
10.1
|
January 7, 2013
|
|
|
10.45
|
Agreement for Repayment of Note by Share Issuance dated as of December 31, 2012 by and among Aemetis, Inc., Aemetis International, Inc., (formerly known as “International Biodiesel, Inc.”), a Nevada corporation and wholly-owned subsidiary of the Company, and Laird Q. Cagan for himself and on behalf of all other holders of interests in the Revolving Line of Credit (as defined in the Agreement).
|
8-K/A
|
000-51354
|
10.1
|
Feb. 27, 2013
|
|
|
10.46
|
Limited Waiver and Amendment No. 2 to Amended and Restated Note Purchase Agreement dated as of February 27, 2013 by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.
|
8-K
|
000-51354
|
10.1
|
March 11, 2013
|
|
|
10.47
|
Amendment No. 1 to Agreement for Repayment of Note by Share Issuance dated as of April 10, 2013 by and among Aemetis, Inc., Aemetis International, Inc., a Nevada corporation and wholly-owned subsidiary of the Company, and Laird Q. Cagan for himself and on behalf of all other holders of interests in the Revolving Line of Credit (as defined in the Agreement).
|
10-K
|
000-51354
|
10.77
|
April 4, 2013
|
|
|
10.48
|
Amendment to the Purchasing Agreement dated March 9, 2011 between J.D. Heiskell Holdings LLC and Aemetis Advanced Fuels Keyes, Inc. dated January 2, 2013.
|
10-K
|
000-51354
|
10.76
|
April 4, 2013
|
|
INDEX TO EXHIBITS
|
||||||
|
Incorporated by Reference
|
|
|||||
|
Exhibit No.
|
Description
|
Form
|
Film No.
|
Exhibit
|
Filing Date
|
Filed Herewith |
|
10.49
|
Limited Waiver and Amendment No.3 to Amended and Restated Note Purchase Agreement dated as of April 15, 2013 by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.
|
8-K
|
000-51354
|
10.1
|
April 16, 2013
|
|
|
10.50
|
Special Bridge Advance dated as of March 29, 2013 by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis, Inc., a Nevada corporation, Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Insight Fund
|
8-K
|
000-51354
|
10.2
|
April 16, 2013
|
|
|
10.51
|
Agreement For Satisfaction of Note by Share and Note Issuance dated as of April 18, 2013 between Aemetis, Inc., Aemetis International, Inc. and Laird Q. Cagan for himself and on behalf of all other holders of interests in the Revolving Line of Credit dated August 17, 2009 as amended.
|
8-K
|
000-51354
|
10.1
|
April 24, 2013
|
|
|
10.52
|
Amended and Restated Heiskell Purchasing Agreement dated May 16, 2013, by and between Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation and a wholly-owned subsidiary of Aemetis, Inc. and J.D. Heiskell Holdings, LLC, a California limited liability company doing business as J.D. Heiskell & Co.*
|
8-K
|
000-51354
|
10.1
|
May 23, 2013
|
|
|
10.53
|
Amended and Restated Aemetis Keyes Grain Procurement and Working Capital Agreement, dated May 2, 2013, by and between Aemetis Advanced Fuels Keyes, Inc., and J.D. Heiskell Holdings, LLC
|
8-K
|
000-51354
|
10.2
|
May 23, 2013
|
|
|
10.54
|
Limited Waiver and Amendment No.5 to Amended and Restated Note Purchase Agreement, dated as of July 26, 2013 by and among
Aemetis, Inc., Aemetis Advanced Fuels Keyes, Inc. Aemetis Facility Keyes, Inc., Third Eye Capital Corporation, an Ontario
corporation, as agent, Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust
|
8-K
|
000-51354
|
10.1
|
July 31, 2013
|
|
|
10.55
|
Limited Waiver and Amendment No.6 to Amended and Restated Note Purchase Agreement, dated as of October 28, 2013 by and among
Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario
corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.
|
8-K
|
000-51354
|
10.1
|
November 1, 2013
|
|
|
14
|
Code of Ethics
|
10-K
|
000-51354
|
14
|
May 20, 2009
|
|
|
Subsidiaries of the Registrant
|
X
|
|||||
|
Consent of Independent Registered Public Accounting Firm
|
X
|
|||||
|
24
|
Power of Attorney (see signature page)
|
X
|
||||
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|
Page
Number
|
||
|
Report of Independent Registered Public Accounting Firm
|
46
|
|
|
Consolidated Financial Statements
|
||
|
47
|
||
|
48
|
||
|
49
|
||
|
Consolidated Statements of Stockholders' Equity (Deficit)
|
50
|
|
|
51-72
|
|
December 31, 2013
|
December 31, 2012
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 4,925,820 | $ | 290,603 | ||||
|
Accounts receivable
|
2,764,646 | 1,360,606 | ||||||
|
Inventories
|
4,097,544 | 4,555,780 | ||||||
|
Prepaid expenses
|
583,891 | 264,243 | ||||||
|
Other current assets
|
335,007 | 374,217 | ||||||
|
Total current assets
|
12,706,908 | 6,845,449 | ||||||
|
Property, plant and equipment, net
|
78,928,129 | 83,893,472 | ||||||
|
Goodwill
|
967,994 | 967,994 | ||||||
|
Intangible assets, net of accumulated amortization of $184,150 and none, as of 2013 and 2012, respectively
|
1,615,850 | 1,800,000 | ||||||
|
Other assets
|
2,923,011 | 3,365,244 | ||||||
|
Total assets
|
$ | 97,141,892 | $ | 96,872,159 | ||||
|
Liabilities and stockholders' equity/(deficit)
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 9,365,585 | $ | 15,070,106 | ||||
|
Current portion of long term secured notes, net of discounts
|
4,400,000 | 26,278,535 | ||||||
|
Current portion of subordinated notes, net of discounts
|
5,317,252 | 329,013 | ||||||
|
Secured notes, net of discounts
|
5,857,104 | 5,756,752 | ||||||
|
Working capital loans and short-term notes
|
2,391,332 | 2,159,291 | ||||||
|
Mandatorily redeemable Series B convertible preferred stock
|
2,539,528 | 2,437,649 | ||||||
|
Other current liabilities
|
6,245,745 | 5,803,857 | ||||||
|
Total current liabilities
|
36,116,546 | 57,835,203 | ||||||
|
Long term debt:
|
||||||||
|
Secured notes, net of discounts
|
67,886,388 | 25,954,536 | ||||||
|
Related party line of credit
|
- | 1,540,074 | ||||||
|
Subordinated notes, net of discounts
|
- | 3,009,101 | ||||||
|
Seller note payable
|
4,869,244 | 4,011,430 | ||||||
|
EB-5 notes payable
|
1,036,863 | 1,006,863 | ||||||
|
Total long term debt
|
73,792,495 | 35,522,004 | ||||||
|
Stockholders' equity/(deficit):
|
||||||||
|
Series B convertible preferred stock, $0.001 par value; 7,235,565 authorized; 2,401,061 and 3,097,725 shares issued and outstanding, respectively (aggregate liquidation preference of $7,203,183 and $9,293,175, respectively)
|
2,401 | 3,098 | ||||||
|
Common stock, $0.001 par value; 400,000,000 authorized; 199,736,862 and 180,281,094 shares issued and outstanding, respectively
|
199,737 | 180,281 | ||||||
|
Additional paid-in capital
|
84,192,552 | 75,457,760 | ||||||
|
Accumulated deficit
|
(94,245,503 | ) | (69,808,294 | ) | ||||
|
Accumulated other comprehensive loss
|
(2,916,336 | ) | (2,317,893 | ) | ||||
|
Total stockholders' equity/(deficit)
|
(12,767,149 | ) | 3,514,952 | |||||
|
Total liabilities and stockholders' equity/(deficit)
|
$ | 97,141,892 | $ | 96,872,159 | ||||
|
2013
|
2012
|
|||||||
|
Revenues
|
$ | 177,513,972 | $ | 189,048,226 | ||||
|
Cost of goods sold
|
159,220,212 | 197,975,173 | ||||||
|
Gross profit/(loss)
|
18,293,760 | (8,926,947 | ) | |||||
|
Research and development expenses
|
538,922 | 620,368 | ||||||
|
Selling, general and administrative expenses
|
15,275,108 | 11,613,357 | ||||||
|
Operating income/(loss)
|
2,479,730 | (21,160,672 | ) | |||||
|
Other income/(expense)
|
||||||||
|
Interest expense
|
||||||||
|
Interest rate expense
|
(11,807,144 | ) | (10,110,748 | ) | ||||
|
Amortization of debt issuance costs
|
(12,468,384 | ) | (7,547,167 | ) | ||||
|
Loss on debt extinguishment
|
(3,708,537 | ) | (9,068,868 | ) | ||||
|
Interest income
|
10,044 | 4,976 | ||||||
|
Gain on bargain purchase
|
- | 42,335,876 | ||||||
|
Gain on sale of assets
|
328,755 | 350,356 | ||||||
|
Other income/(expense)
|
734,092 | (167,275 | ) | |||||
|
Loss before income taxes
|
(24,431,444 | ) | (5,363,522 | ) | ||||
|
Income tax (expense)/benefit
|
(5,765 | ) | 1,081,257 | |||||
|
Net loss
|
(24,437,209 | ) | (4,282,265 | ) | ||||
|
Other comprehensive income
|
||||||||
|
Foreign currency translation adjustment
|
(598,443 | ) | (74,531 | ) | ||||
|
Comprehensive loss
|
$ | (25,035,652 | ) | $ | (4,356,796 | ) | ||
|
Net loss per common share
|
||||||||
|
Basic and diluted
|
$ | (0.13 | ) | $ | (0.03 | ) | ||
|
Weighted average shares outstanding
|
||||||||
|
Basic and diluted
|
191,008,919 | 151,023,977 | ||||||
|
For the tweleve months ended December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Operating activities:
|
||||||||
|
Net loss
|
$ | (24,437,209 | ) | $ | (4,282,265 | ) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities
|
||||||||
|
Share-based compensation
|
1,760,072 | 686,059 | ||||||
|
Depreciation
|
4,636,161 | 3,041,783 | ||||||
|
Inventory provision
|
- | 104,895 | ||||||
|
Amortization expense
|
12,468,384 | 7,543,583 | ||||||
|
Intangibles and other amortization expense
|
253,600 | - | ||||||
|
Change in fair value of warrant liability
|
(197,127 | ) | 97,022 | |||||
|
Loss on extinguishment of debt
|
3,708,537 | 9,068,868 | ||||||
|
Gain on sale of assets
|
(328,755 | ) | (350,356 | ) | ||||
|
Gain on acquisition bargain purchase
|
- | (42,335,876 | ) | |||||
|
Deferred tax liability/(asset)
|
- | (1,085,257 | ) | |||||
|
Changes in assets and liabilities:
|
||||||||
|
Accounts receivable
|
(1,486,830 | ) | 3,113,643 | |||||
|
Inventory
|
210,837 | (740,242 | ) | |||||
|
Prepaid expenses
|
13,535 | 148,166 | ||||||
|
Other current assets and other assets
|
(693,472 | ) | 475,965 | |||||
|
Accounts payable
|
(5,411,595 | ) | 799,620 | |||||
|
Accrued interest expense and fees, net of payments
|
7,007,176 | 4,007,260 | ||||||
|
Other liabilities
|
813,561 | 2,775,405 | ||||||
|
Net cash used in operating activities
|
(1,683,125 | ) | (16,931,727 | ) | ||||
|
Investing activities:
|
||||||||
|
Capital expenditures
|
(1,275,855 | ) | (1,368,395 | ) | ||||
|
Proceeds from the sale of assets
|
1,499,852 | 1,404,166 | ||||||
|
Acquisition of Cilion
|
- | (16,500,000 | ) | |||||
|
Net cash provided (used) in investing activities
|
223,997 | (16,464,229 | ) | |||||
|
Financing activities:
|
||||||||
|
Proceeds from borrowings under secured debt facilities
|
4,800,000 | 39,840,000 | ||||||
|
Repayments of borrowings under secured debt facilities
|
(400,000 | ) | (9,962,259 | ) | ||||
|
Proceeds from borrowings under unsecured and subdebt term notes and working capital lines of credit
|
5,740,856 | 7,325,325 | ||||||
|
Repayments of borrowings under unsecured and subdebt notes and working capital facility
|
(4,973,675 | ) | (3,868,050 | ) | ||||
|
Issuance of Common stock through Equity offering and Warrant exercises
|
1,082,735 | 1,433 | ||||||
|
Net cash provided by financing activities
|
6,249,916 | 33,336,449 | ||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
(155,571 | ) | 100,644 | |||||
|
Net cash and cash equivalents increase for period
|
4,635,217 | 41,137 | ||||||
|
Cash and cash equivalents at beginning of period
|
290,603 | 249,466 | ||||||
|
Cash and cash equivalents at end of period
|
$ | 4,925,820 | $ | 290,603 | ||||
|
Supplemental disclosures of cash flow information, cash paid:
|
||||||||
|
Interest payments
|
$ | 4,522,097 | $ | 2,084,751 | ||||
|
Income tax expense
|
(5,765 | ) | 4,000 | |||||
|
Supplemental disclosures of cash flow information, non-cash transactions:
|
||||||||
|
Issuance of warrants to subordinated debt holders
|
1,127,120 | |||||||
|
Payments of principal, fees and interest by issuance of stock
|
3,616,284 | 11,885,579 | ||||||
|
Issuance of shares to related party for repayment of line of credit
|
821,946 | 4,107,141 | ||||||
|
Issuance of warrants to non-employees to secure procurement and working capital
|
335,617 | - | ||||||
|
Other asset transferred to related party
|
170,000 | - | ||||||
|
Warrant liability transferred to equity upon exercise
|
1,006,648 | - | ||||||
|
Issuance of shares for acquisition
|
- | 12,511,200 | ||||||
|
Beneficial conversion discount on related party debt
|
- | 884,851 | ||||||
|
Seller note payable at fair value
|
- | 3,584,371 | ||||||
|
Accumulated Other
|
||||||||||||||||||||||||||||||||
|
Series B Preferred Stock
|
Common Stock
|
Additional
|
Accumulated
|
Comprehensive
|
Total
|
|||||||||||||||||||||||||||
|
Shares
|
Dollars
|
Shares
|
Dollars
|
Paid-in Capital
|
Deficit
|
Income/(loss)
|
Dollars
|
|||||||||||||||||||||||||
|
Balance at December 31, 2011
|
3,115,225 | $ | 3,115 | 130,746,890 | $ | 130,747 | $ | 45,432,447 | $ | (65,526,029 | ) | $ | (2,243,362 | ) | $ | (22,203,082 | ) | |||||||||||||||
|
Stock-based compensation
|
- | - | 321,965 | 322.00 | 258,271 | - | - | 258,593 | ||||||||||||||||||||||||
|
Shares issued to consultants
|
- | - | 1,000,000 | 1,000 | 426,466 | - | - | 427,466 | ||||||||||||||||||||||||
|
Shares issued to secured lender
|
- | - | 17,699,172 | 17,699 | 10,848,280 | - | - | 10,865,979 | ||||||||||||||||||||||||
|
Issuance and exercise of warrants
|
- | - | 1,432,667 | 1,433 | 1,018,167 | - | - | 1,019,600 | ||||||||||||||||||||||||
|
Beneficial conversion feature on related party note
|
- | - | 884,851 | - | - | 884,851 | ||||||||||||||||||||||||||
|
Conversion of Series B preferred to common stock
|
17,500 | 17 | - | - | - | - | ||||||||||||||||||||||||||
|
Cilion, Inc. merger
|
- | - | 20,000,000 | 20,000 | 12,491,200 | - | - | 12,511,200 | ||||||||||||||||||||||||
|
Conversion of related party note
|
- | - | 9,062,900 | 9,063 | 4,098,078 | - | - | 4,107,141 | ||||||||||||||||||||||||
|
Other comprehensive income
|
- | - | - | - | - | - | (74,531 | ) | (74,531 | ) | ||||||||||||||||||||||
|
Net loss
|
- | - | - | - | - | (4,282,265 | ) | - | (4,282,265 | ) | ||||||||||||||||||||||
|
Balance at December 31, 2012
|
3,097,725 | $ | 3,098 | 180,281,094 | $ | 180,281 | $ | 75,457,760 | $ | (69,808,294 | ) | $ | (2,317,893 | ) | $ | 3,514,952 | ||||||||||||||||
|
Stock-based compensation & options exercised
|
264,005 | 264 | 1,158,940 | - | - | 1,159,204 | ||||||||||||||||||||||||||
|
Shares issued to consultants and other services
|
- | - | 1,767,715 | 1,768 | 599,100 | - | - | 600,868 | ||||||||||||||||||||||||
|
Shares issued to secured lender
|
- | - | 9,872,201 | 9,872 | 3,606,412 | - | - | 3,616,284 | ||||||||||||||||||||||||
|
Issuance and exercise of warrants
|
- | - | 2,638,636 | 2,639 | 1,477,410 | - | - | 1,480,049 | ||||||||||||||||||||||||
|
Conversion of Series B preferred to common stock
|
696,664 | 697 | - | - | - | - | ||||||||||||||||||||||||||
|
Conversion of related party note
|
- | - | 1,826,547 | 1,826 | 820,120 | - | - | 821,946 | ||||||||||||||||||||||||
|
Issuance of common stock through equity offering
|
2,390,000 | 2,390 | 1,072,810 | - | - | 1,075,200 | ||||||||||||||||||||||||||
|
Other comprehensive income
|
- | - | - | - | - | - | (598,443 | ) | (598,443 | ) | ||||||||||||||||||||||
|
Net loss
|
- | - | - | - | - | (24,437,209 | ) | - | (24,437,209 | ) | ||||||||||||||||||||||
| - | - | |||||||||||||||||||||||||||||||
|
Balance at December 31, 2013
|
2,401,061 | $ | 2,401 | 199,736,862 | $ | 199,737 | $ | 84,192,552 | $ | (94,245,503 | ) | $ | (2,916,336 | ) | $ | (12,767,149 | ) | |||||||||||||||
|
●
|
Aemetis Americas, Inc., a Nevada corporation and its subsidiaries AE Biofuels, Inc., a Delaware corporation;
|
|
●
|
Biofuels Marketing, a Delaware corporation;
|
|
●
|
Aemetis International, Inc., a Nevada corporation and its subsidiary International Biofuels, Ltd., a Mauritius corporation and its subsidiary Universal Biofuels Private, Ltd., an India company;
|
|
●
|
Aemetis Technologies, Inc., a Delaware corporation;
|
|
●
|
Aemetis Biochemicals, Inc., a Nevada corporation;
|
|
●
|
Aemetis Biofuels, Inc., a Delaware corporation and its subsidiary Energy Enzymes, Inc., a Delaware corporation;
|
|
●
|
AE Advanced Fuels, Inc., a Delaware corporation and its subsidiaries Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation and Aemetis Facility Keyes, Inc., a Delaware corporation;
|
|
●
|
Aemetis Advanced Fuels, Inc., a Nevada corporation.
|
|
December 31, 2013
|
December 31, 2012
|
|||||||
|
Series B preferred
|
2,401,061 | 3,097,725 | ||||||
|
Common stock options and warrants
|
14,802,721 | 10,309,257 | ||||||
|
Convertible promissory note
|
186,795 | 178,495 | ||||||
|
Total number of potentially dilutive shares excluded from the basic and diluted net in loss per share calculation
|
17,390,577 | 13,585,477 | ||||||
|
●
|
The “India” operating segment encompasses the Company’s 50 million gallon per year nameplate capacity biodiesel plant in Kakinada, India, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius.
|
|
●
|
The “North America” operating segment includes the Company’s 55 million gallons per year nameplate capacity ethanol plant in Keyes, California and the research facilities in College Park, Maryland.
|
|
As of December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Raw materials
|
$ | 597,119 | $ | 2,077,779 | ||||
|
Work-in-progress
|
1,723,866 | 1,672,957 | ||||||
|
Finished goods
|
1,776,559 | 805,044 | ||||||
|
Total inventory
|
$ | 4,097,544 | $ | 4,555,780 | ||||
|
|
As of December 31,
|
|||||||
|
2013
|
2012
|
|||||||
|
Land
|
$ | 2,764,619 | $ | 2,837,780 | ||||
|
Plant and buildings
|
82,355,467 | 83,004,928 | ||||||
|
Furniture and fixtures
|
557,636 | 376,333 | ||||||
|
Machinery and equipment
|
2,076,162 | 2,615,140 | ||||||
|
Construction in progress
|
539,234 | 82,627 | ||||||
|
Total gross property, plant & equipment
|
88,293,118 | 88,916,808 | ||||||
|
Less accumulated depreciation
|
(9,364,989 | ) | (5,023,336 | ) | ||||
|
Total net property, plant & equipment
|
$ | 78,928,129 | $ | 83,893,472 | ||||
|
For the twelve months ending December 31,
|
Amortization
|
|||
|
2014
|
$ | 80,222 | ||
|
2015
|
111,986 | |||
|
2016
|
111,986 | |||
|
2017
|
111,986 | |||
|
2018
|
111,986 | |||
|
Thereafter
|
1,087,684 | |||
|
Total
|
$ | 1,615,850 | ||
|
December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Third Eye Capital term notes
|
$ | 7,191,928 | $ | 6,679,466 | ||||
|
Third Eye Capital revolving credit facility
|
38,349,178 | 23,378,535 | ||||||
|
Third Eye Capital revenue participation term notes
|
9,464,826 | 7,406,224 | ||||||
|
Third Eye Capital acquisition term notes
|
17,280,456 | 14,768,846 | ||||||
|
Cilion shareholder Seller note payable
|
4,869,244 | 4,011,430 | ||||||
|
State Bank of India secured term loan
|
5,857,104 | 5,756,752 | ||||||
|
Revolving line of credit (related party)
|
— | 1,540,074 | ||||||
|
Subordinated notes
|
5,317,252 | 3,338,114 | ||||||
|
EB-5 long term promissory notes
|
1,036,863 | 1,006,863 | ||||||
|
Unsecured working capital loans and short-term notes
|
2,391,332 | 2,159,291 | ||||||
|
Total debt
|
$ | 91,758,183 | $ | 70,045,595 | ||||
|
Less current portion of long-term debt
|
17,965,688 | 34,523,591 | ||||||
|
Total long term debt
|
$ | 73,792,495 | $ | 35,522,004 | ||||
|
A.
|
Term Notes
.
As of December 31, 2013, Aemetis Advanced Fuels Keyes had $7,191,928 in principal and interest outstanding, net of unamortized fair value discounts of $340,114. The Term Notes mature on July 6, 2014*. Interest on the Term Notes accrues at 14% per annum. The Term Notes contain various covenants, including but not limited to, minimum free cash flow and production requirements and restrictions on capital expenditures. On July 26, 2013 and October 28, 2013, the Company received waivers for certain covenants by Amendment No. 5 and Amendment No. 6. Additionally, Amendment No. 5 waived the requirement for minimum monthly base payments, interest payments and mandatory tiered redemption payments in favor of a daily cash flow sweep equal to 20% of cash deposits from operating activities.
|
|
B.
|
Revolving Credit Facility
.
On July 6, 2012 Aemetis Advanced Fuels Keyes entered into a Revolving Credit Facility with a commitment of $18,000,000. Through various amendments discussed above, the amount of the Revolving Loan Facility was increased to approximately $39,000,000. Interest on the Revolving Credit Facility accrues at the prime rate plus 13.75% (17% as of December 31, 2013) payable monthly in arrears. The Revolving Credit Facility matures on July 6, 2014*. As of December 31, 2013 Aemetis Advanced Fuels Keyes had $38,349,178 in principal and interest outstanding, net of unamortized debt issuance costs of $1,791,357, on the credit facility with available credit set aside to pay Third Eye Capital.
|
|
C.
|
Revenue Participation Term Notes
.
The Revenue Participation Note bears interest at 5% per annum and matures on July 6, 2014*. As of December 31, 2013 Aemetis Advanced Fuels Keyes had $9,464,826 in principal and interest outstanding, net of unamortized discounts of $919,486.
|
|
D.
|
Acquisition Term Notes
.
The Acquisition Term Notes accrue interest at prime rate plus 10.75% (14% per annum as of December 31, 2013) and mature on July 6, 2014*. As of December 31, 2013 Aemetis Facility Keyes had $17,280,456 in principal and interest outstanding, net of unamortized discounts of $749,516.
|
|
For the twelve months ending December 31,2013
|
||
|
2014
|
$18,227,013
|
|
|
2015*
|
74,686,860
|
|
|
2016
|
2,223,151
|
|
|
2017
|
1,036,863
|
|
|
Total
|
$96,173,887
|
|
|
Debt discount at 12/31/13
|
(4,415,704)
|
|
|
Total Debt, net of discounts
|
$91,758,183
|
|
For the twelve months ended December 31,
|
||||
|
2014
|
$
|
314,371
|
||
|
2015
|
|
150,118
|
||
|
Total
|
$
|
464,489
|
||
|
Authorized
|
Shares Issued and
|
|||||||||||
|
Shares
|
Outstanding December 31,
|
|||||||||||
|
2013
|
2012
|
|||||||||||
|
Series B preferred stock
|
7,235,565 | 2,401,061 | 3,097,725 | |||||||||
|
Undesignated
|
57,764,435 | — | — | |||||||||
|
|
65,000,000 | 2,401,061 | 3,097,725 | |||||||||
|
●
|
Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B preferred stock;
|
|
●
|
Effect an exchange, reclassification, or cancellation of all or a part of the Series B preferred stock, including a reverse stock split, but excluding a stock split;
|
|
●
|
Effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series B preferred stock; or
|
|
●
|
Alter or change the rights, preferences or privileges of the shares of Series B preferred stock so as to affect adversely the shares of such series.
|
|
Warrants Outstanding & Exercisable
|
Weighted - Average Exercise Price
|
Average Remaining Term in Years
|
||||||||||
|
Outstanding December 31, 2011
|
1,428,590 | 0.35 | 4.08 | |||||||||
|
Granted
|
1,816,000 | 0.001 | - | |||||||||
|
Exercised
|
(1,432,667 | ) | 0.001 | - | ||||||||
|
Expired
|
(5,000 | ) | 3.00 | - | ||||||||
|
Outstanding December 31, 2012
|
1,806,923 | $ | 0.27 | 2.67 | ||||||||
|
Granted
|
5,818,439 | 0.26 | - | |||||||||
|
Exercised
|
(2,638,636 | ) | 0.01 | - | ||||||||
|
Expired
|
(289,002 | ) | 1.18 | - | ||||||||
|
Outstanding December 31, 2013
|
4,697,724 | 0.34 | 4.85 | |||||||||
|
Expected dividend yield
|
0 | % | ||
|
Risk-free interest rate
|
0.26% - 1.82 | % | ||
|
Expected volatility
|
74.09% - 98.78 | % | ||
|
Expected Life (years)
|
2.0 – 10.0 | |||
|
Exercise price
|
$ | 0.001-$0.50 | ||
|
Company stock price
|
$ | 0.32 - $0.82 |
|
Expected dividend yield
|
0 | % | ||
|
Risk-free interest rate
|
0.78% - 1.27 | % | ||
|
Expected volatility
|
76.80% - 78.05 | % | ||
|
Expected Life (years)
|
3.5 – 4.0 | |||
|
Exercise price
|
$ | 0.001 | ||
|
Company stock price
|
$ | 0.32 |
|
Total
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
2013
|
||||||||||||||||
|
Warrant liability
|
$ | 59,593 | $ | - | $ | - | $ | 59,593 | ||||||||
|
2012
|
||||||||||||||||
|
Warrant liability
|
$ | 267,950 | $ | - | $ | - | $ | 267,950 | ||||||||
|
Balance as of December 31, 2011
|
$ | - | ||
|
Issuances of warrant liabilities
|
1,189,095 | |||
|
Exercise of warrant liabilities
|
(1,018,167 | ) | ||
|
Realized and unrealized loss related to change in fair value
|
97,022 | |||
|
Balance as of December 31, 2012
|
$ | 267,950 | ||
|
Issuances of warrant liabilities
|
995,418 | |||
|
Exercise of warrant liabilities
|
(1,006,648 | ) | ||
|
Realized and unrealized loss related to change in fair value
|
(197,127 | ) | ||
|
Balance as of December 31, 2013
|
$ | 59,593 |
|
Shares Available
|
Number of
|
Weighted-Average
|
||||||||||
|
for Grant
|
Shares Outstanding
|
Exercise Price
|
||||||||||
|
Balance as of December 31, 2011
|
1,656,148 | 6,803,701 | 0.94 | |||||||||
|
Authorized
|
1,000,000 | — | — | |||||||||
|
Granted
|
(2,555,000 | ) | 2,555,000 | 0.55 | ||||||||
|
Exercised
|
— | (321,965 | ) | 0.23 | ||||||||
|
Forfeited/Expired
|
1,511,902 | (1,511,902 | ) | 2.17 | ||||||||
|
Balance as of December 31, 2012
|
1,611,134 | 7,524,834 | $ | 0.59 | ||||||||
|
Authorized
|
1,000,000 | — | — | |||||||||
|
Granted
|
(2,876,000 | ) | 2,876,000 | 0.58 | ||||||||
|
Exercised
|
— | (264,005 | ) | 0.33 | ||||||||
|
Forfeited/Expired
|
1,009,332 | (1,009,332 | ) | 1.53 | ||||||||
|
Balance as of December 31, 2013
|
744,466 | 9,127,497 | $ | 0.49 | ||||||||
|
Number of Shares
|
Weighted Average Exercise Price
|
Remaining Contractual Term (In Years)
|
Average Intrinsic Value
1
|
|||||||||||||
|
2013
|
||||||||||||||||
|
Vested
|
5,163,175 | $ | 0.44 | 1.77 | $ | 523,112 | ||||||||||
|
Unvested
|
3,694,322 | 0.57 | 4.11 | 8,931 | ||||||||||||
|
Total
|
9,127,497 | $ | 0.49 | 2.79 | $ | 532,043 | ||||||||||
|
2012
|
||||||||||||||||
|
Vested
|
5,061,850 | $ | 0.63 | 2.21 | $ | 2,081,910 | ||||||||||
|
Unvested
|
2,462,984 | 0.52 | 4.69 | 435,197 | ||||||||||||
|
Total
|
7,524,834 | $ | 0.59 | 3.02 | $ | 2,517,107 | ||||||||||
|
Fiscal Year Ended December 31
|
||||||||
|
2013
|
2012
|
|||||||
|
Expected dividend yield
|
0 | % | 0 | % | ||||
|
Risk-free interest rate
|
0.13% - 0.67 | % | 0.28% - 0.38 | % | ||||
|
Expected volatility
|
60.39% - 79.70 | % | 79.08 | % | ||||
|
Expected Life (years)
|
1.0 – 3.0 | 2.0 – 3.0 | ||||||
|
Weighted average fair value per share of common stock
|
$ | 0.28 | $ | 0.26 | ||||
|
Number of Shares
|
Weighted Average Exercise Price
|
Remaining Contractual Term (In Years)
|
Average Intrinsic Value
2
|
|||||||||||||
|
2013
|
||||||||||||||||
|
Vested
|
690,000 | $ | 0.55 | 3.85 | $ | - | ||||||||||
|
Unvested
|
287,500 | 0.55 | 3.85 | - | ||||||||||||
|
Total
|
977,500 | $ | 0.55 | 3.85 | $ | - | ||||||||||
|
2012
|
||||||||||||||||
|
Vested
|
402,500 | $ | 0.55 | 4.85 | $ | 60,375 | ||||||||||
|
Unvested
|
575,000 | 0.55 | 4.85 | 86,250 | ||||||||||||
|
Total
|
977,500 | $ | 0.55 | 4.85 | $ | 146,625 | ||||||||||
|
J.D. Heiskell & Company:
|
||||||
|
2013
|
2012
|
|||||
|
Sales
|
||||||
|
Ethanol
|
$
|
106,565,941
|
$
|
128,830,630
|
||
|
Distillers Grains
|
26,490,413
|
35,468,559
|
||||
|
Corn Oil
|
2,609,061
|
2,582,858
|
||||
|
Corn Purchases
|
95,999,548
|
156,984,918
|
||||
|
Grain Sorghum Purchases
|
11,522,666
|
-
|
||||
|
Accounts Receivable
|
641,147
|
394,784
|
||||
|
Accounts Payable
|
2,227,828
|
2,650,013
|
||||
|
For the twelve months ended December 31,
months ended
|
||||||||
|
Statement of Operations Data
|
2013 | 2012 | ||||||
|
Revenues
|
||||||||
|
India
|
$ | 32,816,122 | $ | 13,547,620 | ||||
|
North America
|
144,697,850 | 175,500,606 | ||||||
|
Total revenues
|
$ | 177,513,972 | $ | 189,048,226 | ||||
|
Cost of goods sold
|
||||||||
|
India
|
$ | 28,722,704 | $ | 14,191,098 | ||||
|
North America
|
130,497,508 | 183,784,075 | ||||||
|
Total cost of goods sold
|
$ | 159,220,212 | $ | 197,975,173 | ||||
|
Gross profit/(loss)
|
||||||||
|
India
|
$ | 4,093,418 | $ | (643,478 | ) | |||
|
North America
|
14,200,342 | (8,283,469 | ) | |||||
|
Total gross income/(loss)
|
$ | 18,293,760 | $ | (8,926,947 | ) | |||
|
Total Assets Data
|
Year Ended December 31
|
|||||||
|
2013
|
2012
|
|||||||
|
India
|
$ | 13,958,695 | $ | 15,597,333 | ||||
|
North America
|
83,183,197 | 81,274,826 | ||||||
|
Total Assets
|
$ | 97,141,892 | $ | 96,872,159 | ||||
|
For the three months ended
|
For the year ended
|
|||||||||||||||||||
|
March 31,
|
June 30,
|
September 30,
|
December 31,
|
December 31,
|
||||||||||||||||
|
2013
|
2013
|
2013
|
2013
|
2013
|
||||||||||||||||
|
Revenues
|
$ | 19,420,214 | $ | 47,352,509 | $ | 56,687,910 | $ | 54,053,339 | $ | 177,513,972 | ||||||||||
|
Cost of goods sold
|
19,172,500 | 43,602,242 | 53,652,334 | 42,793,136 | 159,220,212 | |||||||||||||||
|
Gross profit
|
247,714 | 3,750,267 | 3,035,576 | 11,260,203 | 18,293,760 | |||||||||||||||
|
Research and development expenses
|
228,759 | 123,822 | 115,099 | 71,242 | 538,922 | |||||||||||||||
|
Selling, general and administrative expenses
|
4,215,546 | 3,983,544 | 3,878,786 | 3,197,232 | 15,275,108 | |||||||||||||||
|
Operating income/(loss)
|
(4,196,591 | ) | (357,099 | ) | (958,309 | ) | 7,991,729 | 2,479,730 | ||||||||||||
|
Other income/(expense)
|
||||||||||||||||||||
|
Interest expense
|
||||||||||||||||||||
|
Interest rate expense
|
(2,670,702 | ) | (2,912,590 | ) | (2,932,592 | ) | (3,291,260 | ) | (11,807,144 | ) | ||||||||||
|
Amortization expense
|
(2,274,262 | ) | (6,071,548 | ) | (2,019,779 | ) | (2,102,795 | ) | (12,468,384 | ) | ||||||||||
|
Loss on debt extinguishment
|
(956,480 | ) | (231,191 | ) | (2,520,866 | ) | - | (3,708,537 | ) | |||||||||||
|
Interest income
|
348 | 1,424 | 7,974 | 298 | 10,044 | |||||||||||||||
|
Gain on sale of assets
|
126,160 | 47,774 | 107,759 | 47,062 | 328,755 | |||||||||||||||
|
Other income/(expense)
|
163,122 | (69,228 | ) | 27,032 | 613,166 | 734,092 | ||||||||||||||
|
Income /(Loss) before income taxes
|
(9,808,405 | ) | (9,592,458 | ) | (8,288,781 | ) | 3,258,200 | (24,431,444 | ) | |||||||||||
|
Income tax expense
|
(5,600 | ) | - | (165 | ) | (5,765 | ) | |||||||||||||
|
Net income /(loss)
|
(9,814,005 | ) | (9,592,458 | ) | (8,288,781 | ) | 3,258,035 | (24,437,209 | ) | |||||||||||
|
Other comprehensive income
|
||||||||||||||||||||
|
Foreign currency translation adjustment
|
199,250 | (599,566 | ) | (274,988 | ) | 76,861 | (598,443 | ) | ||||||||||||
|
Comprehensive (loss)/income
|
$ | (9,614,755 | ) | $ | (10,192,024 | ) | $ | (8,563,769 | ) | $ | 3,334,896 | $ | (25,035,652 | ) | ||||||
|
Net (loss)/income per common share
|
||||||||||||||||||||
|
Basic
|
$ | (0.05 | ) | $ | (0.05 | ) | $ | (0.04 | ) | $ | 0.02 | $ | (0.13 | ) | ||||||
|
Diluted
|
$ | (0.05 | ) | $ | (0.05 | ) | $ | (0.04 | ) | $ | 0.02 | $ | (0.13 | ) | ||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||
|
Basic
|
182,234,236 | 189,636,949 | 193,901,845 | 198,056,980 | 191,008,919 | |||||||||||||||
|
Diluted
|
182,234,236 | 189,636,949 | 193,901,845 | 202,718,409 | 191,008,919 | |||||||||||||||
|
For the three months ended
|
For the year
|
|||||||||||||||||||
|
Ended
|
||||||||||||||||||||
|
March 31, 2012
|
June 30, 2012
|
September 30, 2012
|
December 31, 2012
|
December 31, 2012
|
||||||||||||||||
|
Revenues
|
44,195,776 | 44,279,866 | 53,408,202 | 47,164,382 | 189,048,226 | |||||||||||||||
|
Cost of goods sold
|
46,454,288 | 46,300,806 | 55,670,850 | 49,549,229 | 197,975,173 | |||||||||||||||
|
Gross loss
|
(2,258,512 | ) | (2,020,940 | ) | (2,262,648 | ) | (2,384,847 | ) | (8,926,947 | ) | ||||||||||
|
Research and development
|
192,617 | 148,704 | 142,498 | 136,549 | 620,368 | |||||||||||||||
|
Selling, general and administrative expenses
|
1,962,841 | 2,412,495 | 2,551,415 | 4,686,606 | 11,613,357 | |||||||||||||||
|
Operating loss
|
(4,413,970 | ) | (4,582,139 | ) | (4,956,561 | ) | (7,208,002 | ) | (21,160,672 | ) | ||||||||||
|
Other income/(expense)
|
||||||||||||||||||||
|
Interest income
|
348 | 1,840 | 348 | 2,440 | 4,976 | |||||||||||||||
|
Interest expense
|
(3,965,047 | ) | (5,304,917 | ) | (3,376,796 | ) | (5,011,155 | ) | (17,657,915 | ) | ||||||||||
|
Other income/(expense)
|
18,211 | (99,569 | ) | 54,219 | (140,136 | ) | (167,275 | ) | ||||||||||||
|
Gain on acquisition bargain purchase
|
- | - | 42,335,876 | - | 42,335,876 | |||||||||||||||
|
Loss on debt extingishment
|
- | - | (9,068,868 | ) | - | (9,068,868 | ) | |||||||||||||
|
Gain on sales of assets
|
- | 236,830 | - | 113,526 | 350,356 | |||||||||||||||
|
Income/(loss) before income taxes
|
(8,360,458 | ) | (9,747,955 | ) | 24,988,218 | (12,243,327 | ) | (5,363,522 | ) | |||||||||||
|
Income taxes benefit/(expense)
|
(4,000 | ) | - | 1,085,257 | - | 1,081,257 | ||||||||||||||
|
Net income/(loss)
|
(8,364,458 | ) | (9,747,955 | ) | 26,073,475 | (12,243,327 | ) | (4,282,265 | ) | |||||||||||
|
Other comprehensive income/(loss)
|
||||||||||||||||||||
|
Foreign currency translation adjustment
|
310,983 | (226,977 | ) | 336,285 | (494,822 | ) | (74,531 | ) | ||||||||||||
|
Comprehensive income/(loss)
|
(8,053,475 | ) | (9,974,932 | ) | 26,409,760 | (12,738,149 | ) | (4,356,796 | ) | |||||||||||
|
Income/(loss) per common share attributable to Aemetis, Inc.
|
||||||||||||||||||||
|
Basic
|
(0.06 | ) | (0.07 | ) | 0.15 | (0.07 | ) | (0.03 | ) | |||||||||||
|
Diluted
|
(0.06 | ) | (0.07 | ) | 0.15 | (0.07 | ) | (0.03 | ) | |||||||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||
|
Basic
|
131,128,280 | 133,239,456 | 168,583,985 | 170,734,618 | 151,023,977 | |||||||||||||||
|
Diluted
|
131,128,280 | 133,239,456 | 176,559,067 | 170,734,618 | 151,023,977 | |||||||||||||||
|
Year Ended December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Current:
|
||||||||
|
Federal
|
—
|
—
|
||||||
|
State and local
|
$
|
5,765
|
$
|
4,000
|
||||
|
Foreign
|
—
|
—
|
||||||
|
5,765
|
4,000
|
|||||||
|
Deferred:
|
||||||||
|
Federal
|
—
|
(933,849
|
) | |||||
|
State and local
|
—
|
(151,408
|
) | |||||
|
Foreign
|
—
|
—
|
||||||
|
Income tax expense/(benefit)
|
$
|
5,765
|
$
|
(1,081,257
|
) | |||
|
Year Ended December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
United States
|
$
|
(25,712,533
|
) |
$
|
(2,981,086
|
) | ||
|
Foreign
|
281,089
|
(2,382,436)
|
) | |||||
|
Loss before income taxes
|
$
|
(24,431,444
|
) |
$
|
(5,363,522
|
) | ||
|
Year Ended December 31,
|
||||||||
|
2013
|
2012
|
|||||||
|
Income tax expense (benefit) at the federal statutory rate
|
(8,306,690 | ) | (1,823,598 | ) | ||||
|
State tax expense (benefit)
|
(695,240 | ) | (476,437 | ) | ||||
|
Foreign tax rate differential
|
219,762 | 475,342 | ||||||
|
Stock-based compensation
|
555,883 | 382,030 | ||||||
|
Interest Expense
|
327,647 | 429,673 | ||||||
|
Loss on Debt Extinguishment
|
1,162,032 | 3,707,620 | ||||||
|
Gain on Bargain Purchase
|
0 | (16,727,979 | ) | |||||
|
Other
|
69,196 | (159,845 | ) | |||||
|
Cilion Transaction Costs
|
0 | 302,271 | ||||||
|
Credits
|
- | (150,452 | ) | |||||
|
Valuation Allowance
|
6,673,176 | 12,960,118 | ||||||
|
Income Tax Expense
|
5,765 | (1,081,257 | ) | |||||
|
Effective Tax Rate
|
-0.02 | % | 20.16 | % | ||||
|
Year Ended December 31,
|
||||||||
|
Deferred Tax Assets & (Liabilities)
|
2013
|
2012
|
||||||
|
Org, Start-up and Intangible Assets
|
9,302,636 | 9,898,832 | ||||||
|
Stock Based Comp
|
114,946 | 233,365 | ||||||
|
Prop., Plant, and Equip.
|
(18,929,925 | ) | (14,546,837 | ) | ||||
|
NOLs and Credits
|
49,139,117 | 38,790,667 | ||||||
|
Convertible Debt
|
(5,325 | ) | (9,382 | ) | ||||
|
Ethanol Credits
|
1,500,000 | 1,500,000 | ||||||
|
Debt Extinguishment
|
2,535,798 | 1,822,458 | ||||||
|
Other, net
|
1,544,586 | 839,555 | ||||||
|
Subtotal
|
45,201,833 | 38,528,658 | ||||||
|
Valuation Allowance
|
(45,201,833 | ) | (38,528,658 | ) | ||||
|
Deferred tax assets (liabilities)
|
- | - | ||||||
|
United States — Federal
|
2009 – present
|
||
|
United States — State
|
2009– present
|
||
|
India
|
2007 – present
|
||
|
Mauritius
|
2007 – present
|
|
Assets
|
2013
|
2012
|
||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$ | 13,718 | $ | - | ||||
|
Intercompany receivables
|
27,627,159 | 20,802,877 | ||||||
|
Total current assets
|
27,640,877 | 20,802,877 | ||||||
|
Investments in Subsidiaries, net of advances
|
||||||||
|
Investment in Aemetis International, Inc.
|
2,678,525 | 3,060,684 | ||||||
|
Investment in Aemetis Americas, Inc
|
- | 116,144 | ||||||
|
Total investments in Subsidiaries, net of advances
|
2,678,525 | 3,176,828 | ||||||
|
Other assets
|
23,095 | 23,095 | ||||||
|
Total Assets
|
$ | 30,342,497 | $ | 24,002,800 | ||||
|
Liabilities & stockholders' equity(deficit)
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$ | 3,397,294 | $ | 4,037,137 | ||||
|
Outstanding checks in excess of cash
|
- | 25,773 | ||||||
|
Mandatorily redeemable Series B convertibe preferred
|
2,539,528 | 2,437,649 | ||||||
|
Other current liabilities
|
1,677,835 | 2,174,608 | ||||||
|
Total current liabilities
|
7,614,657 | 8,675,167 | ||||||
|
Subsidiary obligation in excess of investment
|
||||||||
|
Investment in AE Advanced Fuels, Inc.
|
31,324,660 | 8,400,675 | ||||||
|
Investment in Aemetis Americas, Inc
|
246,676 | - | ||||||
|
Investment in Aemetis Biofuels, Inc.
|
2,741,279 | 2,624,575 | ||||||
|
Investment in Aemetis Technologies, Inc.
|
833,318 | 438,375 | ||||||
|
Investment in Biofuels Marketing, Inc.
|
349,056 | 349,056 | ||||||
|
Total subsidiary obligation in excess of investment
|
35,494,989 | 11,812,681 | ||||||
|
Total long term liabilities
|
35,494,989 | 11,812,681 | ||||||
|
Stockholders' equity(deficit)
|
||||||||
|
Series B Preferred convertible stock
|
2,401 | 3,098 | ||||||
|
Common stock
|
199,737 | 180,281 | ||||||
|
Additional paid-in capital
|
84,192,552 | 75,457,760 | ||||||
|
Accumulated deficit
|
(94,245,503 | ) | (69,808,294 | ) | ||||
|
Accumulated other comprehensive loss
|
(2,916,336 | ) | (2,317,893 | ) | ||||
|
Total stockholders' equity(deficit)
|
(12,767,149 | ) | 3,514,952 | |||||
|
Total liabilities & stockholders' equity(deficit)
|
$ | 30,342,497 | $ | 24,002,800 | ||||
|
2013
|
2012
|
||||||||
|
Equity in subsidiary losses
|
$ | (22,134,091 | ) | $ | (12,496 | ) | |||
|
Selling, general and administrative expenses
|
2,686,828 | 2,302,944 | |||||||
|
Operating loss
|
(24,820,919 | ) | (2,315,440 | ) | |||||
|
Other income/(expense)
|
|||||||||
|
Interest expense
|
(187,417 | ) | (1,865,803 | ) | |||||
|
Other income/(expense)
|
576,892 | (97,022 | ) | ||||||
|
Loss before income taxes
|
(24,431,444 | ) | (4,278,265 | ) | |||||
|
Income taxes expense
|
(5,765 | ) | (4,000 | ) | |||||
|
Net loss
|
$ | (24,437,209 | ) | $ | (4,282,265 | ) | |||
|
Other comprehensive loss
|
|||||||||
|
Foreign currency translation adjustment
|
(598,443 | ) | (74,531 | ) | |||||
|
Comprehensive loss
|
$ | (25,035,652 | ) | $ | (4,356,796 | ) | |||
|
2013
|
2012
|
|||||||
|
Operating activities:
|
||||||||
|
Net loss
|
(24,437,209 | ) | (4,282,265 | ) | ||||
|
Adjustments to reconcile net loss to
|
||||||||
|
net cash provided/(used) in operating activities:
|
||||||||
|
Stock-based compensation
|
1,760,072 | 686,059 | ||||||
|
Amortization of debt issuance discount
|
- | 400,997 | ||||||
|
Change in fair value of warrant liability
|
(197,127 | ) | 97,022 | |||||
|
Changes in assets and liabilities:
|
||||||||
|
Subsidiary portion of net losses
|
22,134,091 | 12,496 | ||||||
|
Prepaid expenses
|
- | 4,668 | ||||||
|
Accounts payable
|
(639,843 | ) | 236,887 | |||||
|
Accrued interest expense
|
- | 682,983 | ||||||
|
Other liabilities
|
(177,896 | ) | 288,203 | |||||
|
Net cash used in operating activities
|
(1,557,912 | ) | (1,872,950 | ) | ||||
|
Investing activities:
|
||||||||
|
Change in outstanding checks in excess of cash
|
(25,773 | ) | 25,773 | |||||
|
Subsidiary advances, net
|
514,668 | 9,417,256 | ||||||
|
Net cash provided in investing activities
|
488,895 | 9,443,029 | ||||||
|
Financing activities:
|
||||||||
|
Proceeds from borrowings under secured debt facilities
|
- | 840,000 | ||||||
|
Repayments of borrowings under secured debt facilities
|
- | (8,412,259 | ) | |||||
|
Equity Offering
|
1,075,200 | - | ||||||
|
Warrants exercised
|
7,535 | 1,433 | ||||||
|
Net cash provided by/(used in)by financing activities
|
1,082,735 | (7,570,826 | ) | |||||
|
Net increase/(decrease) in cash and cash equivalents
|
13,718 | (747 | ) | |||||
|
Cash and cash equivalents at beginning of period
|
- | 747 | ||||||
|
Cash and cash equivalents at end of period
|
$ | 13,718 | $ | - | ||||
|
Supplemental disclosures of cash flow information, cash paid:
|
||||||||
|
Interest payments
|
4,522,097 | 2,084,751 | ||||||
|
Income tax expense
|
5,765 | 4,000 | ||||||
|
Supplemental disclosures of cash flow information, non-cash transactions:
|
||||||||
|
Issuance of warrants to non-employees to secure procurement and working capital
|
335,617 | |||||||
|
Issuance of warrants to subordinated debt holders
|
1,127,120 | |||||||
|
Issuance of shares for acquisition
|
- | 12,511,200 | ||||||
|
Payments of principal, fees and interest by issuance of stock
|
3,616,284 | 11,885,579 | ||||||
|
Issuance of shares to related party for repayment of line of credit
|
821,946 | 4,107,141 | ||||||
|
Beneficial conversion discount on related party debt
|
- | 884,851 | ||||||
|
Other asset transferred to related party
|
170,000 | |||||||
| Warrant liability transferred to equity upon exercise | 1,006,648 | |||||||
|
●
|
Operating the Keyes plant in the current positive margin environment;
|
|
●
|
Continuing to incorporate lower-cost, non-food advanced biofuels feedstock at the Keyes plant;
|
|
●
|
Attracting investors to financing arrangements including working with Advanced BioEnergy LP to issue up to $35 million of additional EB-5 notes at 3% interest rate;
|
|
●
|
Refinance the senior debt with a lender who is able to offer terms conducive to the long term financing of the Keyes plant
|
|
●
|
Restructuring or refinance the State Bank of India note to allow for additional working capital and reduce current financing costs;
|
|
●
|
Securing higher volumes of international shipments from the Kakinada, India biodiesel and refined glycerin facility; and
|
|
●
|
Continuing to expand in the India market as the subsidy on diesel is reduced to zero by June 2014.
|
|
Aemetis, Inc.
|
|
|
/s/ E
RIC
A. M
C
A
FEE
|
|
|
Eric A. McAfee
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
Name
|
Title
|
Date
|
||
|
/s/ E
RIC
A. M
C
A
FEE
|
Chairman/Chief Executive Officer
|
March 11, 2014
|
||
|
Eric A. McAfee
|
(Principal Executive Officer and Director)
|
|||
|
/s/
Todd Waltz
|
Chief Financial Officer
|
March 11, 2014
|
||
|
Todd Waltz
|
(Principal Financial and Accounting Officer)
|
|
||
|
/s/
Francis Barton
|
Director
|
March 11, 2014
|
||
|
Fran Barton
|
||||
|
/s/
John R. Block
|
Director
|
March 11, 2014
|
||
|
John R. Block
|
||||
|
/s/
Dr. Steven Hutcheson
|
Director
|
March 11, 2014
|
||
|
Dr. Steven Hutcheson
|
||||
|
/s/
Harold Sorgenti
|
Director
|
March 11, 2014
|
||
|
Harold Sorgenti
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|